We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Multigene Expression Profiling Assays Compared for Cancer

By LabMedica International staff writers
Posted on 19 Jul 2019
A cost-effectiveness analysis recently published has added another factor to the ongoing competition and debate between various companies offering genomic breast cancer recurrence assays.

Gene expression profiling testing is available to aid in chemotherapy decision-making when traditional clinicopathological predictors are insufficient to accurately determine recurrence risk in women with axillary lymph node-negative, hormone receptor-positive, and human epidermal growth factor-receptor 2-negative early-stage breast cancer.

A team of scientists led by those at Western University (London, ON, Canada) examined the cost-effectiveness of incorporating multigene assays into standard practice. More...
A decision model was built to project lifetime clinical and economic consequences of different adjuvant treatment-guiding strategies. The gene expression profiling (GEP) assay that were compared were the 12-gene recurrence score (RS) assay EndoPredict, the 58-gene RS assay Prosigna, and the 21-gene RS assay Oncotype DX.

To model the impact of gene expression testing on patient outcomes, the group inputted risk distributions for the three assays alongside 10-year survival estimates from the ATAC data. They combined these factors with rates of chemotherapy administration from a recent Canadian field evaluation of adjuvant therapy decision-making with and without Oncotype Dx testing.

Based on their calculations, the scientists concluded that EndoPredict, Prosigna, and Oncotype DX had cost-effectiveness ratios of USD 36,274, USD 48,525, and USD 74,911 per quality-adjusted life year (QALY) gained. This corresponded to total gains of 379, 284.3, and 189.5 QALYs/year and total budgets of USD 12.9, USD 14.2, and USD 16.6 million/year, respectively. The data also suggested that the NanoString and Myriad tests could improve the cost-effectiveness of gene expression testing and offer higher value for the money, with Myriad taking the top spot in terms of cost-effectiveness.

Importantly, the authors stated that they believe prospective evidence is still needed to confirm the findings from their modeling using the ATAC data, and as such, "results should be interpreted with caution." For one, the model treated all three tests similarly, assuming relative benefit from adjuvant chemotherapy to be the same across patient risk groups. But since the cutoff for the team's analysis, the field has now seen the finalization and publication of the prospective TAILORx trial, which confirmed that Genomic Health's Oncotype DX assay, unlike other tests, does directly predict benefit or lack of benefit from chemotherapy. Altering the model to reflect this could thus change the QALY results. The study was published May 27, 2019, in the journal The Pharmacogenomics Journal.

Related Links:
Western University


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Serological Pipet Controller
PIPETBOY GENIUS
New
DNA/RNA Extraction/Purification Kit
Nucleic Acid Extraction or Purification Kit
New
Host Response Immunoassay Test
MeMed BV
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.